Euroopan unioni -
romania -
EMA (European Medicines Agency)
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Euroopan unioni -
romania -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Euroopan unioni -
romania -
EMA (European Medicines Agency)
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
Euroopan unioni -
romania -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
Romania -
romania -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
pemetrexed novamed 100 mg
seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 100mg - antimetaboliti analogi ai acidului folic
Romania -
romania -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
pemetrexed novamed 500 mg
seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 500mg - antimetaboliti analogi ai acidului folic
Romania -
romania -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
pemetrexed seacross 100 mg
seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 100mg - antimetaboliti analogi ai acidului folic
Romania -
romania -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
pemetrexed seacross 500 mg
seacross pharma (europe) limited - irlanda - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 500mg - antimetaboliti analogi ai acidului folic
Euroopan unioni -
romania -
EMA (European Medicines Agency)
savene
clinigen healthcare b.v. - dexrazoxan clorhidrat - extravasarea materialelor de diagnosticare și terapeutică - toate celelalte produse terapeutice - savene este indicat pentru tratamentul extravazării antraciclinei.
Romania -
romania -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
viviflor
haupt pharma amareg gmbh - germania - combinatii (lactobacillus acidophilus+estriolum) - compr. vag. - antiinfectioase (excl. combinatii cu corticosteroizi) alte antiinfectioase si antiseptice